ENLIGHTEN-1

Summary: 

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly XXXXX in Adult Participants with Obesity or Overweight, without Type 2 Diabetes (ENLIGHTEN-1)

Type of study:  

Recruiting study

Is this Study Applicable for RSI Scheme?  

For the purpose of the RSI scheme this study will count as a Recruiting Study: Consent Taken at Site

Commercial Study - Site Identification form required to be completed, please find Site ID form uploaded to study documents link below. 

If you have been contacted directly by sponsor/CRO to take part in this study, you are NOT required to complete the NIHR Site Identification form.  Please confirm by return email that you are in direct contact with sponsor/CRO and are completing their questionnaire.  If you require any support with this process, please let us know and we would be happy to discuss. 

Practice Activity: 

Please see Part B (N.B. a Schedule of Events is currently unavailable)

Practice Eligibility Criteria: 

We are looking to identify primary care sites, they must have previous experience in commercial phase 3 CTIMP trials and access to DXA imaging provider.

Practice Target: 

7 participants

Is this Study Applicable for the Associate PI Scheme?  

Not applicable for this study

Research Costs: 

Commercial research studies follow a national tariff guideline.  Click here for more information on the tariff or download the tariff by clicking here.